Review article
Post covid 19 pulmonary fibrosis. Is it real threat?

https://doi.org/10.1016/j.ijtb.2020.11.003Get rights and content

Highlights

  • Considering millions of covid 19 cases worldwide, even small proportion of post covid lung fibrosis is worrisome.

  • Elderly patient who require ICU care and mechanical ventilation are the highest risk to develop lung fibrosis.

  • At present, no fully proven options are available for the treatment of post COVID 19 pulmonary fibrosis.

  • Antifibrotics in the acute phase of severe disease with ARDS may reduce fibrosis.

Abstract

After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.

Keywords

Covid 19
Pulmonary fibrosis
Antifibrotic
ARDS

Cited by (0)

View Abstract